Objectives: To develop and validate a self-efficacy measure of diabetes self-management, the Lifestyle Self-Efficacy Scale for Latinos with Diabetes (LSESLD), designed for low-income, Spanish-speaking Latinos with diabetes.
Design: Quantitative and qualitative methods.
Setting: Community health centers in central and western Massachusetts.
Participants: Low-income Latinos (N = 252) enrolled in a randomized diabetes self-management intervention trial.
Measures: Construct validity, internal consistency, sensitivity to change over time.
Results: The LSESLD demonstrated good internal consistency (Cronbach's alpha = .85), reasonable construct validity (moderate, significant associations between the LSESLD and validated measures of diabetes knowledge, dietary intake, physical activity, blood glucose self-monitoring, and HbA1c values), and sensitivity to intervention-related changes over time.
Conclusion: The LSESLD is a reliable and valid research instrument assessing self-efficacy related to diabetes self-management among low-income, Spanish-speaking populations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956449 | PMC |
Cureus
December 2024
Saúde Oeste Family Health Unit, Braga Local Health Unit, Braga, PRT.
Aim: Diabetes mellitus is a prevalent disease in the Portuguese population and is associated with significant morbidity and mortality. Its proper therapeutic management is multifactorial, with lifestyle habits having a major impact. Studies show that poorer metabolic control is associated with deficient knowledge related to diabetes, lower self-efficacy, and limited patient empowerment.
View Article and Find Full Text PDFClin Neuropsychol
January 2025
Department of Psychiatry, Brown University Health, Providence, RI, USA.
Older adults with cognitive impairment are at risk of medication-taking errors. This study assessed the impact of providing medication adherence feedback to cognitively impaired older adults. Forty participants with mild cognitive impairment or mild dementia had their medication adherence electronically monitored for 8 weeks.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Aims: This analysis evaluated whether gastrointestinal (GI) adverse events (AEs) including nausea, vomiting, diarrhoea (N/V/D) and dyspepsia were associated with weight reduction with tirzepatide across the SURMOUNT-1 to -4 trials.
Materials And Methods: SURMOUNT-1 to -4 were global Phase 3 clinical trials evaluating the safety and efficacy of tirzepatide among participants with obesity or overweight with or without type 2 diabetes (T2D). Participants were randomly assigned to receive once weekly subcutaneous tirzepatide or placebo.
BMJ Open
January 2025
Amsterdam University Medical Centres, Amsterdam, Noord-Holland, The Netherlands.
Introduction: Type 2 diabetes mellitus (T2DM) is a major burden on public health worldwide. To reduce adverse events and complications, effective T2DM self-management is required. Self-management and glycaemic control are generally poorer in lower educated people compared with higher educated people.
View Article and Find Full Text PDFContemp Nurse
January 2025
Faculty of Health, University of Technology Sydney, 235 Jones Street, Ultimo, NSW 2007, Australia.
Indigenous Australians are disproportionately affected by diabetes, with a diagnosis rate nearly four times higher than people from a non-Indigenous background. This health disparity highlights the urgent need for healthcare providers to develop cultural empathy - a critical competency for delivering culturally safe and person-centered care. Cultural empathy is essential for building trust and effective communication in diabetes education and management within Indigenous people.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!